Stelexis Therapeutics procures $43 mln Series A

New York-based Stelexis Therapeutics, a cancer therapeutics firm, has secured $43 million in Series A financing. Stelexis is backed by Deerfield.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!